Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software.

Diabetes Technology & Therapeutics
Satish K GargPeter A Gottlieb

Abstract

Management of type 1 diabetes could be significantly improved with the availability of computerized insulin algorithms for home use. This was a 1-year open label randomized control trial involving 123 adult subjects with type 1 diabetes (hemoglobin A1c values 7.5-11%) assigned to either the insulin guidance software (ACCU-CHEK) [Roche, Indianapolis, IN] Advisor) for personal data assistant (experimental group) or the control group. The primary aim of the study was to see if subjects using insulin dosing advisor software will improve glucose control over 1 year. The principal end point was an improvement in A1c at 6 and 12 months by >or=0.4%. Baseline demographics were similar in the two groups. Mean A1c was 8.54+/-0.11% in the control group and 8.42+/-0.11% (P=0.4265) in the experimental group. The mean A1c was significantly lower from 3 to 12 months in the experimental group (P<0.02). A1c reduction of >or=0.6% was maintained at 12 months in the experimental group. Also, a significantly higher number of subjects achieved A1c <7.5% in the experimental group from 3 to 9 months. Within target range glycemia (70-150 mg/dL) was higher in the experimental group at 3-9 months without any change in insulin dose or weight. Above target ...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jun 10, 1993·The New England Journal of Medicine·D M Nathan
Apr 12, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·H P ChaseS K Garg
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Mar 1, 2007·Diabetes Care·Kendra VehikDana Dabelea
Jun 15, 2007·Diabetes Technology & Therapeutics·Timothy S BaileySatish K Garg

❮ Previous
Next ❯

Citations

Dec 20, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ides M Colin, Isabelle Paris
Jun 28, 2011·Diabetes Technology & Therapeutics·Alfred PenfornisSophie Borot
Aug 3, 2012·Diabetes Technology & Therapeutics·Howard C Zisser
Apr 15, 2009·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Karolina PetersonRudolf Chlup
Feb 26, 2016·Diabetes Technology & Therapeutics·Dominic EhrmannBernhard Kulzer
Mar 10, 2009·Diabetes/metabolism Research and Reviews
Jun 24, 2014·IEEE Journal of Biomedical and Health Informatics·Pau HerreroChristofer Toumazou
Mar 31, 2016·Diabetes Technology & Therapeutics·Vikash Dadlani, Yogish C Kudva
Mar 4, 2015·Computer Methods and Programs in Biomedicine·Pau HerreroChristofer Toumazou
May 31, 2014·Journal of Diabetes Science and Technology·Signe Schmidt, Kirsten Nørgaard
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Miranda LangendamRob J P M Scholten
Jun 20, 2018·Diabetes Technology & Therapeutics·Rayhan A LalDavid M Maahs
Jun 4, 2019·Diabetes Technology & Therapeutics·Jens Otto Broby MadsenUNKNOWN ABC consortium
Apr 1, 2017·Expert Opinion on Drug Delivery·Timothy S Bailey, Jenine Y Stone
Oct 14, 2020·Diabetes Technology & Therapeutics·Parizad AvariMonika Reddy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.